Related Experiment Videos
Reversible restrictive cardiomyopathy due to light-chain deposition disease
Motoyuki Nakamura1, Mamoru Satoh, Shugo Kowada
1Department of Internal Medicine, Iwate Medical University, Morioka, Japan. nkmrmoto@iwate-med.ac.jp
Insights
Systemic light-chain deposition can cause restrictive cardiomyopathy. This study shows cardiac function may significantly improve after treating the underlying multiple myeloma, suggesting potential reversibility.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Systemic light-chain deposition from plasma cell dyscrasias can lead to restrictive cardiomyopathy and diastolic dysfunction.
- The potential for reversibility of these cardiac manifestations after treating the underlying plasma cell disorder remains largely unknown.
- Cardiac involvement in plasma cell dyscrasias is often presumed to be cardiac amyloidosis.
Observation:
- This report details the first case of cardiac light-chain deposition secondary to multiple myeloma.
- The patient experienced significant improvement in echocardiographic and biochemical markers of cardiac function.
- These improvements occurred following successful remission of the multiple myeloma.
Findings:
- Cardiac light-chain deposition disease in the context of multiple myeloma demonstrated reversible cardiac dysfunction.
- Echocardiographic and biochemical parameters of cardiac function showed dramatic amelioration.
- Complete remission of the underlying plasma cell disorder was associated with improved cardiac outcomes.
Implications:
- Restrictive cardiomyopathy caused by light-chain deposition may be a reversible condition.
- Early diagnosis and treatment of plasma cell dyscrasias could lead to better cardiac prognoses.
- This finding challenges the assumption of irreversible cardiac damage in light-chain deposition disease.
Abstract:
Systemic light-chain deposition due to plasma cell dyscrasias manifests as a form of restrictive cardiomyopathy with diastolic ventricular dysfunction. Although these manifestations are likely to be cardiac amyloidosis, whether these pathological conditions are reversible after treatment of the underlying plasma cell disorders is unknown. To our knowledge, we describe the first patient with cardiac light-chain deposition due to multiple myeloma in whom echocardiographic and biochemical factors of cardiac function were ameliorated dramatically after remission of this disorder. We emphasize that restrictive cardiomyopathy due to light-chain deposition may be reversible and have a relatively better prognosis after remission of plasma cell dyscrasias.